Published in Cancer Res on July 15, 2003
Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia (2005) 3.16
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
Clustering analysis of SAGE data using a Poisson approach. Genome Biol (2004) 1.58
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45
Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn (2007) 1.44
Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn (2010) 1.27
ISOLATE: a computational strategy for identifying the primary origin of cancers using high-throughput sequencing. Bioinformatics (2009) 1.22
Towards a holistic, yet gene-centered analysis of gene expression profiles: a case study of human lung cancers. J Biomed Biotechnol (2006) 1.22
Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer (2008) 1.21
Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res (2009) 1.20
The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res (2008) 1.16
A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn (2006) 1.08
Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res (2008) 1.07
Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn Pathol (2010) 1.06
Defining NOTCH3 target genes in ovarian cancer. Cancer Res (2012) 0.97
Expression cartography of human tissues using self organizing maps. BMC Bioinformatics (2011) 0.96
Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors. Ann Surg Oncol (2013) 0.92
A gene expression classifier of node-positive colorectal cancer. Neoplasia (2009) 0.91
High-throughput avian molecular sexing by SYBR green-based real-time PCR combined with melting curve analysis. BMC Biotechnol (2008) 0.88
Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling. Surgery (2012) 0.87
Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases. Clin Exp Metastasis (2011) 0.86
The modern histopathologist: in the changing face of time. Diagn Pathol (2008) 0.85
Machine learning approaches to supporting the identification of photoreceptor-enriched genes based on expression data. BMC Bioinformatics (2006) 0.82
Clustering-based approaches to SAGE data mining. BioData Min (2008) 0.79
From peas to "chips" - the new millennium of molecular biology: a primer for the surgeon. World J Surg Oncol (2003) 0.76
Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site. J Mol Diagn (2010) 0.76
Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary. Pharmacogenomics J (2016) 0.75
hSAGEing: an improved SAGE-based software for identification of human tissue-specific or common tumor markers and suppressors. PLoS One (2010) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
International network of cancer genome projects. Nature (2010) 20.35
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Pancreatic cancer. Lancet (2011) 8.54
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Ductal carcinoma in situ of the breast. N Engl J Med (2004) 6.63
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
The antisense transcriptomes of human cells. Science (2008) 6.29
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
Dicer function is essential for lung epithelium morphogenesis. Proc Natl Acad Sci U S A (2006) 4.87
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol (2008) 4.70
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
The predictive capacity of personal genome sequencing. Sci Transl Med (2012) 4.64
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature (2010) 4.53